Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02070458
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT02046070
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)Adult Acute Monocytic Leukemia (M5b)
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 4
- Registration Number
- NCT02030405
- Locations
- 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 118
- Registration Number
- NCT02004275
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01953783
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01939899
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01912222
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT01850524
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01830816
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers Medical City, Dallas, Texas, United States
🇺🇸Institute of Oncology Hematology Biomedical Research, Laredo, Texas, United States
🇺🇸University of Kansas Cancer Center, Clinical Research Center, Fairway, Kansas, United States
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT01659658
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.